Protalix BioTherapeutics Inc (PBDA.DU)
| Previous close | 1.0905 |
| Open | 1.0885 |
| Bid | 1.0485 x N/A |
| Ask | 1.0920 x N/A |
| Day's range | 1.0490 - 1.0885 |
| 52-week range | 1.0250 - 3.1430 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- GuruFocus.com
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
PR NewswireProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update.
